160 related articles for article (PubMed ID: 9552992)
1. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
Breteler MM
BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
[No Abstract] [Full Text] [Related]
2. Selegiline and excess mortality.
Oakes D
Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
[No Abstract] [Full Text] [Related]
3. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
4. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
5. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
Counsell C
BMJ; 1998 Dec; 317(7172):1586. PubMed ID: 9836669
[No Abstract] [Full Text] [Related]
6. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
7. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
8. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
9. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Heinonen E; Myllylä V
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
[No Abstract] [Full Text] [Related]
10. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Coyle J; Hobson P; Meara J
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
[No Abstract] [Full Text] [Related]
11. Controversies in the treatment of Parkinson's disease.
Hely MA; Morris JG
Curr Opin Neurol; 1996 Aug; 9(4):308-13. PubMed ID: 8858190
[TBL] [Abstract][Full Text] [Related]
12. Deprenyl's neuroprotective action remains unresolved.
van Hilten JJ; Bloem BR; Klaassen AA
Ann Neurol; 1996 Aug; 40(2):266-7. PubMed ID: 8773615
[No Abstract] [Full Text] [Related]
13. Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O
Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
[No Abstract] [Full Text] [Related]
14. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
Mizuno Y; Kondo T; Kuno S; Nomoto M; Yanagisawa N
Clin Neuropharmacol; 2010; 33(1):1-4. PubMed ID: 19935410
[TBL] [Abstract][Full Text] [Related]
15. New drugs for Parkinson's disease.
Hodges LC; Rapp CG
J Neurosci Nurs; 1990 Aug; 22(4):254-7. PubMed ID: 2144560
[TBL] [Abstract][Full Text] [Related]
16. Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.
Abrams KR
BMJ; 1998 Apr; 316(7139):1183-4. PubMed ID: 9552993
[No Abstract] [Full Text] [Related]
17. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
18. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
19. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
20. Pallidotomy in Parkinson's disease.
Temlett JA
S Afr Med J; 1996 Oct; 86(10):1248-9. PubMed ID: 8955725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
